As punishment for allegedly promoting potent, rapid-onset fentanyl products like Actiq and Fentora for use by non-cancer patients and deceptively marketing their opioids like oxycodone by downplaying addiction, Teva Pharmaceuticals, in a preliminary agreement with Pennsylvania Attorney General Josh Shapiro, must pay $4.25 billion in cash over 13 years to states and local government, per a news release from the state Attorney General’s office.
Further details of the settlement are under negotiation, per the report. The agreement is the result of a multistate investigation of six drug manufacturers and three distributors, such as Anda, for their roles in the opioid epidemic. Prior to the Teva agreement, Amerisource Bergen, Cardinal Health, McKesson, and Johnson & Johnson came to a $26 billion agreement with Shapiro, according to the report.
Thus far, both parties have agreed to the following:
Shapiro’s office spearheaded the investigation, which was joined by California, Illinois, Iowa, Massachusetts, New York, North Carolina, Tennessee, Texas, Vermont, Virginia, and Wisconsin, per the report.
Read more on the preliminary agreement here.
See also:
PA Part Of $48 Billion Opioid Epidemic Settlement
PA Attorney General: Purdue Pharma Helped Fuel Drug Crisis
French Pharmaceutical Giant Roquette Opening New HQ and Innovation Center in Lower Gwynedd
Opioid Settlement will Send $1B to Pennsylvania
Ireland’s Almac Group Investing $93.5M into Harleysville HQ Expansion, Bringing 355 New Jobs
